J. Hatlebakk

发表

Gastroesophageal Acid Reflux Control 5 Years After Antireflux Surgery, Compared With Long-term Esomeprazole Therapy.

C. Ell, J. Galmiche, L. Lundell, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial

C. Ell, J. Galmiche, L. Lundell, 2008, Gut.

One-week Esomeprazole Treatment: an Effective Confirmatory Test in Patients with Suspected Gastroesophageal Reflux Disease

E. Toth, J. Hatlebakk, F. Johnsson, 2003 .

Symptom-relieving Effect of Esomeprazole 40 mg Daily in Patients with Heartburn

J. Hatlebakk, F. Johnsson, A. Klintenberg, 2003, Scandinavian journal of gastroenterology.

Endoscopic Classification of Gastro-esophageal Reflux Disease

A. Berstad, J. Hatlebakk, 2001 .

Endoscopic grading of reflux oesophagitis: what observations correlate with gastro-oesophageal reflux?

A. Berstad, J. Hatlebakk, 1997, Scandinavian journal of gastroenterology.

Gastro‐oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole

I. Wiklund, J. Dent, S. Riley, 1998 .

Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group.

I. Wiklund, J. Dent, S. Riley, 1998, European journal of gastroenterology & hepatology.

Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease.

I. Wiklund, L. Lundell, P. Miettinen, 2001, Journal of the American College of Surgeons.

Heartburn treatment in primary care: randomised, double blind study for 8 weeks

A. Berstad, T. Bernklev, P. Mowinckel, 1999, BMJ.

Clinical presentation, diagnosis, pathogenesis and treatment options for lymphocytic colitis (Review).

T. Hausken, J. Hatlebakk, M. El-Salhy, 2013, International journal of molecular medicine.

Medical therapy. Management of the refractory patient.

D. Castell, P. Katz, J. Hatlebakk, 1999, Gastroenterology clinics of North America.

Impact of gastroesophageal reflux disease on patients' daily lives: a European observational study in the primary care setting

J. Gisbert, L. Agréus, J. Zapardiel, 2009, Health and quality of life outcomes.

Intragastric maldistribution of a liquid meal in patients with reflux oesophagitis assessed by three dimensional ultrasonography

O. Gilja, T. Hausken, A. Berstad, 2002, Gut.

[A pregnant woman with vomiting and breathing difficulties].

J. Hatlebakk, D. A. L. Hoff, K. Øvrebø, 2014, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

Patients with Endoscopic Gastritis and/or Duodenitis Improve Markedly Following Eradication of Helicobacter pylori, Although Less So Than Patients with Ulcers

A. Berstad, S. Olafsson, J. Hatlebakk, 2002, Scandinavian journal of gastroenterology.

Seven‐year follow‐up of a randomized clinical trial comparing proton‐pump inhibition with surgical therapy for reflux oesophagitis

L. Lundell, P. Miettinen, A. Walan, 2007, The British journal of surgery.

The dynamics of the oesophageal squamous epithelium ‘normalisation’ process in patients with gastro‐oesophageal reflux disease treated with long‐term acid suppression or anti‐reflux surgery

C. Ell, J. Galmiche, L. Lundell, 2017, Alimentary pharmacology & therapeutics.

Long-term effect on symptoms and quality of life of maintenance therapy with esomeprazole 20 mg daily: a post hoc analysis of the LOTUS trial

C. Ell, J. Galmiche, L. Lundell, 2015, Current medical research and opinion.

Original article Long-term effect on symptoms and quality of life of maintenance therapy with esomeprazole 20mg daily: a post hoc analysis of the LOTUS trial

J. Galmiche, L. Lundell, J. Hatlebakk, 2015 .

Long‐term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies

C. Ell, J. Galmiche, L. Lundell, 2015, Alimentary pharmacology & therapeutics.

Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole

A. Berstad, H. Maartmann-Moe, P. Brandtzaeg, 1997, Gut.

Supplementation with Low Doses of a Cod Protein Hydrolysate on Glucose Regulation and Lipid Metabolism in Adults with Metabolic Syndrome: A Randomized, Double-Blind Study

T. Hausken, I. Brønstad, J. Hatlebakk, 2020, Nutrients.

Irritable bowel syndrome patients who are not likely to respond to fecal microbiota transplantation

T. Hausken, J. Hatlebakk, M. El-Salhy, 2022, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

The Effect of Supplementation with Low Doses of a Cod Protein Hydrolysate on Satiety Hormones and Inflammatory Biomarkers in Adults with Metabolic Syndrome: A Randomized, Double-Blind Study

T. Hausken, I. Brønstad, J. Hatlebakk, 2020, Nutrients.

Interaction between diet and gastrointestinal endocrine cells

T. Hausken, J. Hatlebakk, M. El-Salhy, 2016, Biomedical reports.

Stomach antral endocrine cells in patients with irritable bowel syndrome

O. Gilja, T. Hausken, J. Hatlebakk, 2014, International journal of molecular medicine.

Abnormalities in endocrine and immune cells are correlated in dextran-sulfate-sodium-induced colitis in rats

O. Gilja, J. Hatlebakk, M. El-Salhy, 2016, Molecular medicine reports.

Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole

A. Berstad, J. Hatlebakk, 1997, Alimentary pharmacology & therapeutics.

Gastroesophageal reflux in morbidly obese patients treated with gastric banding or vertical banded gastroplasty.

A. Viste, K. Svanes, J. Hatlebakk, 1998, Annals of surgery.

Acute effect of a cod protein hydrolysate on postprandial acylated ghrelin concentration and sensations associated with appetite in healthy subjects: a double-blind crossover trial

T. Hausken, E. Lied, I. Brønstad, 2019, Food & nutrition research.

Abnormal rectal endocrine cells in patients with irritable bowel syndrome

O. Gilja, T. Hausken, J. Hatlebakk, 2014, Regulatory Peptides.

The role of peptide YY in gastrointestinal diseases and disorders

T. Hausken, J. Hatlebakk, M. El-Salhy, 2012, International journal of molecular medicine.

Chromogranin A cell density in the large intestine of Asian and European patients with irritable bowel syndrome

O. Gilja, T. Hausken, S. Gonlachanvit, 2017, Scandinavian Journal of Gastroenterology.

Changes in enteroendocrine and immune cells following colitis induction by TNBS in rats

J. Hatlebakk, M. El-Salhy, 2016, Molecular medicine reports.

Standardization of Surgical Technique in Antireflux Surgery: The LOTUS Trial Experience

C. Ell, J. Galmiche, L. Lundell, 2008, World Journal of Surgery.

Effects of omeprazole or anti-reflux surgery on lower oesophageal sphincter characteristics and oesophageal acid exposure over 10 years

L. Lundell, H. Myrvold, T. Lind, 2017, Scandinavian journal of gastroenterology.

Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease.

T. Hausken, A. Berstad, L. Nesje, 1995, Scandinavian journal of gastroenterology.

Amelioration of Severe TNBS Induced Colitis by Novel AP-1 and NF-κB Inhibitors in Rats

O. Gilja, T. Hausken, K. Umezawa, 2014, TheScientificWorldJournal.

Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5‐year follow‐up in the LOTUS trial

C. Ell, J. Galmiche, L. Lundell, 2012, Alimentary pharmacology & therapeutics.

Mechanosensation and Mucosal Blood Perfusion in the Esophagus of Healthy Volunteers Studied with a Multimodal Device Incorporating Laser Doppler Flowmetry and Endosonography

S. Odegaard, H. Gregersen, D. Liao, 2010, Digestive Diseases and Sciences.

The Effect of Anaerobically Cultivated Human Intestinal Microbiota Compared to Fecal Microbiota Transplantation on Gut Microbiota Profile and Symptoms of Irritable Bowel Syndrome, a Double-Blind Placebo-Controlled Study

T. Hausken, J. Hatlebakk, G. Lied, 2022, Microorganisms.

Current status of fecal microbiota transplantation for irritable bowel syndrome

T. Hausken, J. Hatlebakk, M. El-Salhy, 2021, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Long‐term effects of fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome

O. Gilja, T. Hausken, A. B. Kristoffersen, 2021, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome

T. Hausken, J. Hatlebakk, J. Valeur, 2021, World journal of gastroenterology.

Effects of a Cod Protein Hydrolysate Supplement on Symptoms, Gut Integrity Markers and Fecal Fermentation in Patients with Irritable Bowel Syndrome

T. Hausken, I. Brønstad, J. Hatlebakk, 2019, Nutrients.

The predictive value of symptoms in gastro-oesophageal reflux disease.

A. Berstad, J. Hatlebakk, 1995, Scandinavian journal of gastroenterology. Supplement.

High densities of serotonin and peptide YY cells in the colon of patients with lymphocytic colitis.

T. Hausken, J. Hatlebakk, M. El-Salhy, 2012, World journal of gastroenterology.

Low Densities of Serotonin and Peptide YY Cells in the Colon of Patients with Irritable Bowel Syndrome

T. Hausken, J. Hatlebakk, M. El-Salhy, 2011, Digestive Diseases and Sciences.

Density of Musashi-1-positive stem cells in the stomach of patients with irritable bowel syndrome

T. Hausken, J. Hatlebakk, M. El-Salhy, 2020, Molecular medicine reports.

Changes in the symptom pattern and the densities of large-intestinal endocrine cells following Campylobacter infection in irritable bowel syndrome: a case report

T. Hausken, J. Hatlebakk, M. El-Salhy, 2013, BMC Research Notes.

Gastroparesis Symptoms Associated with Intestinal Hypomotility: An Explorative Study Using Wireless Motility Capsule

E. Søfteland, T. Hausken, M. Biermann, 2021, Clinical and experimental gastroenterology.

CEG_A_304854 133..144

E. Søfteland, T. Hausken, M. Biermann, 2021 .

Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis.

L. Lundell, P. Miettinen, A. Walan, 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Ineffective esophageal motility: the most common motility abnormality in patients with GERD-associated respiratory symptoms

D. Castell, P. Katz, J. Hatlebakk, 1999, American Journal of Gastroenterology.

The effect of a controlled gluten challenge in a group of patients with suspected non‐coeliac gluten sensitivity: A randomized, double‐blind placebo‐controlled challenge

J. Hatlebakk, G. Lied, N. Hovdenak, 2018, Neurogastroenterology and Motility.

A Randomized, Comparative Trial of a Potassium-Competitive Acid Blocker (AZD0865) and Esomeprazole for the Treatment of Patients With Nonerosive Reflux Disease

J. Dent, P. Lundborg, P. Kahrilas, 2008, The American Journal of Gastroenterology.

Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction–Recommendations of the Nordic Working Group

A. Drewes, M. Simrén, L. Agréus, 2016, Scandinavian journal of pain.

Diet and Irritable Bowel Syndrome, with a Focus on Appetite-Regulating Gut Hormones

T. Hausken, J. Hatlebakk, M. El-Salhy, 2014 .

How to select patients for antireflux surgery? The ICARUS guidelines (international consensus regarding preoperative examinations and clinical characteristics assessment to select adult patients for antireflux surgery)

Scott B. Johnson, G. Boeckxstaens, A. Bredenoord, 2019, Gut.

Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones

T. Hausken, J. Hatlebakk, M. El-Salhy, 2019, Nutrients.

Pharmacokinetic Optimisation in the Treatment of Gastro-Oesophageal Reflux Disease

A. Berstad, A Berstad, J. Hatlebakk, 1996, Clinical pharmacokinetics.

Medical therapy of gastroesophageal reflux disease

J. Galmiche, E. Coron, J. Hatlebakk, 2007, Current opinion in gastroenterology.

Gastrointestinal neuroendocrine peptides/amines in inflammatory bowel disease

O. Gilja, T. Hausken, J. Hatlebakk, 2017, World journal of gastroenterology.

Reduction in duodenal endocrine cells in irritable bowel syndrome is associated with stem cell abnormalities.

T. Hausken, J. Hatlebakk, M. El-Salhy, 2015, World journal of gastroenterology.

Controversies in dyspepsia.

O. Gilja, T. Hausken, A. Berstad, 2001, The European journal of surgery. Supplement. : = Acta chirurgica. Supplement.

Irritable bowel syndrome: recent developments in diagnosis, pathophysiology, and treatment

O. Gilja, T. Hausken, J. Hatlebakk, 2014, Expert review of gastroenterology & hepatology.

Is irritable bowel syndrome an organic disorder?

O. Gilja, T. Hausken, J. Hatlebakk, 2014, World journal of gastroenterology.

Lansoprazole in the treatment of reflux oesophagitis: a survey of clinical studies

A. Berstad, J. Hatlebakk, 1993, Alimentary pharmacology & therapeutics.

The relation between celiac disease, nonceliac gluten sensitivity and irritable bowel syndrome

O. Gilja, T. Hausken, J. Hatlebakk, 2015, Nutrition Journal.

Stability of gastric secretory inhibition during 6-month treatment with omeprazole in patients with gastroesophageal reflux disease

A. Berstad, J. Hatlebakk, S. Tefera, 2001, American Journal of Gastroenterology.

Nasal and salivary pepsin as a biomarker for gastroesophageal reflux in chronic rhinosinusitis

R. Omdal, J. T. Kvaløy, S. Steinsvåg, 2019, Rhinology Online.

Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis

A. Berstad, J. Hatlebakk, 1997, Alimentary pharmacology & therapeutics.

Gastro-oesophageal reflux during 3 months of therapy with ranitidine in reflux oesophagitis.

A. Berstad, J. Hatlebakk, 1996, Scandinavian journal of gastroenterology.

Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial.

A. Berstad, P. Unge, P. Ekström, 1993, Scandinavian journal of gastroenterology.

Gastro-oesophageal reflux in patients with chronic rhino-sinusitis investigated with multichannel impedance - pH monitoring.

T. Grimstad, J. T. Kvaløy, S. Steinsvåg, 2017, Rhinology.

Gastric Accommodation Studied by Ultrasonography in Patients with Reflux Esophagitis

O. Gilja, A. Berstad, J. Hatlebakk, 2001, Digestive Diseases and Sciences.

Endoscopy in gastro-oesophageal reflux disease.

J. Hatlebakk, 2010, Best practice & research. Clinical gastroenterology.

Long-Term Outcome of Microscopic Esophagitis in Chronic GERD Patients Treated With Esomeprazole or Laparoscopic Antireflux Surgery in the LOTUS Trial

C. Ell, J. Galmiche, L. Lundell, 2010, The American Journal of Gastroenterology.

The cost of long term therapy for gastro-oesophageal reflux disease: a randomised trial comparing omeprazole and open antireflux surgery

L. Lundell, P. Miettinen, R. Julkunen, 2001, Gut.

Long-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. The Nordic GORD Study Group.

I. Wiklund, L. Lundell, P. Miettinen, 2000, European journal of gastroenterology & hepatology.

Chromogranin A Cell Density as a Diagnostic Marker for Lymphocytic Colitis

T. Hausken, J. Hatlebakk, M. El-Salhy, 2012, Digestive Diseases and Sciences.

Low-grade inflammation in the rectum of patients with sporadic irritable bowel syndrome.

T. Hausken, J. Hatlebakk, M. El-Salhy, 2013, Molecular medicine reports.

Abnormal differentiation of stem cells into enteroendocrine cells in rats with DSS-induced colitis

O. Gilja, K. Umezawa, J. Hatlebakk, 2017, Molecular medicine reports.

Densities of rectal peptide YY and somatostatin cells as biomarkers for the diagnosis of irritable bowel syndrome

O. Gilja, T. Hausken, J. Hatlebakk, 2015, Peptides.

Interaction between ingested nutrients and gut endocrine cells in patients with irritable bowel syndrome (Review)

O. Gilja, T. Hausken, J. Hatlebakk, 2014, International journal of molecular medicine.

Endocrine cells in the ileum of patients with irritable bowel syndrome.

O. Gilja, T. Hausken, J. Hatlebakk, 2014, World journal of gastroenterology.

Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study

O. Gilja, T. Hausken, J. Hatlebakk, 2019, Gut.

A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial

G. Boeckxstaens, D. Silberg, H. Denison, 2011, Gut.

Validation of the GerdQ questionnaire for the diagnosis of gastro‐oesophageal reflux disease

B. Wernersson, J. Hatlebakk, C. Jonasson, 2013, Alimentary pharmacology & therapeutics.

Dilatation therapy for dysphagia in patients with upper esophageal sphincter dysfunction--manometric and symptomatic response.

D. Castell, J. Castell, P. Katz, 1998, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

The fecal microbiota transplantation response differs between patients with severe and moderate irritable bowel symptoms

T. Hausken, J. Hatlebakk, M. El-Salhy, 2022, Scandinavian journal of gastroenterology.

Proton pump inhibitors: better acid suppression when taken before a meal than without a meal

D. Castell, P. Katz, J. Hatlebakk, 2000, Alimentary pharmacology & therapeutics.

Study protocol of the Bergen brain-gut-microbiota-axis study

A. Lundervold, A. Lundervold, O. Gilja, 2020, Medicine.

Bismuth-based combination therapy for Helicobacter pylori-associated peptic ulcer disease (metronidazole for eradication, ranitidine for pain).

T. Hausken, A. Berstad, L. Nesje, 1996, American Journal of Gastroenterology.

Irritable bowel syndrome: the role of gut neuroendocrine peptides.

T. Hausken, I. Seim, L. Chopin, 2012, Frontiers in bioscience.

Spiramycin in triple therapy of Helicobacter pylori‐associated peptic ulcer disease. An open pilot study with 12‐month follow‐up

T. Hausken, A. Berstad, L. Nesje, 1995, Alimentary pharmacology & therapeutics.

The possible role of gastrointestinal endocrine cells in the pathophysiology of irritable bowel syndrome

O. Gilja, T. Hausken, J. Hatlebakk, 2017, Expert review of gastroenterology & hepatology.

Eradication of Helicobacter pylori Does Not Increase Acid Reflux in Patients with Mild to Moderate Reflux Oesophagitis

J. Hatlebakk, S. Tefera, A. Berstad, 2002, Scandinavian journal of gastroenterology.

Review article: gastric acidity − comparison of esomeprazole with other proton pump inhibitors

J. Hatlebakk, 2003, Alimentary pharmacology & therapeutics.

Ultrasound imaging for assessing functions of the GI tract

O. Gilja, T. Hausken, J. Hatlebakk, 2021, Physiological measurement.

The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation

O. Gilja, T. Hausken, D. A. Sangnes, 2018, PloS one.

Chronic constipation and treatment options (Review).

O. Gilja, T. Hausken, J. Hatlebakk, 2014, Molecular medicine reports.

Diagnostic approach to suspected irritable bowel syndrome.

J. Hatlebakk, M. Hatlebakk, 2004, Best practice & research. Clinical gastroenterology.

Colonoscopy with mucosal biopsies in young rats: a model for experimental gastroenterology.

T. Hausken, J. Hatlebakk, M. El-Salhy, 2013, Molecular medicine reports.

Effects of varying dietary content of fermentable short‐chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome

T. Hausken, K. Brokstad, J. Hatlebakk, 2017, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational study

J. Gisbert, L. Agréus, J. Nuevo, 2009, Health and quality of life outcomes.

Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial.

C. Ell, J. Galmiche, L. Lundell, 2011, JAMA.

Efficacy of fecal microbiota transplantation for patients with irritable bowel syndrome at three years after transplantation.

O. Gilja, T. Hausken, J. Hatlebakk, 2022, Gastroenterology.

Gastroesophageal Reflux and Rhinosinusitis

S. Steinsvåg, J. Hatlebakk, E. Katle, 2013, Current Allergy and Asthma Reports.

Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels

O. Gilja, T. Hausken, D. A. Sangnes, 2019, Scandinavian journal of gastroenterology.

Increasing the Dose and/or Repeating Faecal Microbiota Transplantation (FMT) Increases the Response in Patients with Irritable Bowel Syndrome (IBS)

T. Hausken, J. Hatlebakk, M. El-Salhy, 2019, Nutrients.

Gastric accommodation in healthy subjects studied by ultrasound, manometry, and impedancemetry

O. Gilja, T. Hausken, J. Hatlebakk, 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Chronic fatigue in patients with unexplained self-reported food hypersensitivity and irritable bowel syndrome: validation of a Norwegian translation of the Fatigue Impact Scale

A. Berstad, J. Hatlebakk, J. Valeur, 2013, Clinical and experimental gastroenterology.

Advanced imaging and visualization in gastrointestinal disorders.

Ivan Viola, Odd Helge Gilja, Trygve Hausken, 2007, World journal of gastroenterology.

Medical or Surgical Management of GERD Patients with Barrett’s Esophagus: The LOTUS Trial 3-Year Experience

C. Ell, J. Galmiche, L. Lundell, 2008, Journal of Gastrointestinal Surgery.

Management of gastro-oesophageal reflux disease in primary care: a European observational study

J. Gisbert, L. Agréus, M. Tafalla, 2009, Current medical research and opinion.

Consultation rates and characteristics of gastro-oesophageal reflux disease in primary care: A European observational study

J. Gisbert, L. Agréus, M. Tafalla, 2009, The European journal of general practice.

Supplementation with cod protein hydrolysate in older adults: a dose range cross-over study

T. Hausken, E. Lied, I. Brønstad, 2019, Journal of Nutritional Science.

[Treatment of gastroesophageal reflux disease].

Dag Arne Lihaug Hoff, J. Hatlebakk, Jan Gunnar Hatlebakk, 2007, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

Do patients with functional chest pain have neuroplastic reorganization of the pain matrix? A diffusion tensor imaging study

A. Drewes, J. Frøkjær, G. Dimcevski, 2014, Scandinavian journal of pain.

Peroral endoscopic pyloromyotomy for primary pyloric stenosis

A. Viste, T. Hausken, J. Hatlebakk, 2015, Endoscopy.

One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease.

E. Toth, J. Hatlebakk, F. Johnsson, 2001, Scandinavian journal of gastroenterology.

Enteroendocrine, Musashi 1 and neurogenin 3 cells in the large intestine of Thai and Norwegian patients with irritable bowel syndrome

O. Gilja, T. Hausken, S. Gonlachanvit, 2017, Scandinavian journal of gastroenterology.

Clinical trial design in adult reflux disease: a methodological workshop

P. Moayyedi, J. Dent, B. Delaney, 2008, Alimentary pharmacology & therapeutics.

Irritable bowel syndrome: treatment options

T. Hausken, J. Hatlebakk, M. El-Salhy, 2012 .

Changes of gastric mucosal architecture during long‐term omeprazole therapy: results of a randomized clinical trial

L. Lundell, P. Miettinen, A. Walan, 2006, Alimentary pharmacology & therapeutics.

Duodenal Chromogranin A Cell Density as a Biomarker for the Diagnosis of Irritable Bowel Syndrome

O. Gilja, T. Hausken, J. Hatlebakk, 2014, Gastroenterology research and practice.

Irritable Bowel Syndrome: Diagnosis, Pathogenesis and Treatment Options

J. Hatlebakk, D. Gundersen, 2014 .

Overlapping of irritable bowel syndrome with erosive esophagitis and the performance of Rome criteria in diagnosing IBS in a clinical setting

O. Gilja, J. Hatlebakk, M. El-Salhy, 2019, Molecular medicine reports.

Possible role of peptide YY (PYY) in the pathophysiology of irritable bowel syndrome (IBS)

T. Hausken, J. Hatlebakk, M. El-Salhy, 2019, Neuropeptides.

W1111 Safety Profile in GERD Patients 5 Yrs After Laparoscopic Antireflux Surgery or Long-Term Treatment With Esomeprazole 20-40mg Daily in the Lotus Study

C. Seiler, C. Ell, J. Galmiche, 2010 .

Laparoscopic Antireflux Surgery vs Esomeprazole Treatment for Chronic GERD

C. Ell, J. Galmiche, L. Lundell, 2011 .

The role of diet in the pathogenesis and management of irritable bowel syndrome (Review).

T. Hausken, J. Hatlebakk, M. El-Salhy, 2012, International journal of molecular medicine.

Gastric Emptying of Low- and High-Caloric Liquid Meals Measured Using Ultrasonography in Healthy Volunteers

T. Hausken, J. Hatlebakk, E. Nikitina, 2019, Ultrasound International Open.

The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease.

J. Hatlebakk, F. Johnsson, L. Carling, 1997, Scandinavian journal of gastroenterology.

Association between adherence to concomitant proton pump inhibitor therapy in current NSAID users and upper gastrointestinal complications

F. Granath, L. Lundell, J. Kouri, 2013, European journal of gastroenterology & hepatology.

Sensation evoked by esophageal distension in functional chest pain patients depends on mechanical stress rather than on ischemia

B. T. Hjertaker, S. Odegaard, H. Gregersen, 2010, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Novel developments in non-erosive and erosive gastroesophageal reflux disease

J. Galmiche, E. Coron, J. Hatlebakk, 2006, Current opinion in gastroenterology.

M1875 Efficacy and Tolerability of the Novel Reflux Inhibitor, AZD3355, As Add-On Treatment in GERD Patients with Symptoms Despite Proton Pump Inhibitor Therapy

G. Boeckxstaens, D. Silberg, H. Denison, 2009 .

Evaluation of the usefulness of colonoscopy with mucosal biopsies in the follow-up of TNBS-induced colitis in rats.

T. Hausken, J. Hatlebakk, M. El-Salhy, 2013, Molecular medicine reports.

Structured management strategy versus usual care for gastroesophageal reflux disease: rationale for pooled analysis of five European cluster-randomized trials

L. Agréus, V. Garrigues, M. Tafalla, 2011, Therapeutic advances in gastroenterology.

Structured management strategy based on the Gastro-oesophageal Reflux Disease (GERD) Questionnaire (GerdQ) vs. usual primary care for GERD: pooled analysis of five cluster-randomised European studies

E. Guallar, L. Agréus, V. Garrigues, 2012, International journal of clinical practice.

Follow-up on 242 patients with peptic ulcer disease one year after eradication of Helicobacter pylori infection.

T. Hausken, A. Berstad, L. Nesje, 1995, Hepato-gastroenterology.

Long‐term management of gastro‐oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial

I. Wiklund, L. Lundell, P. Miettinen, 2000 .

Factors affecting the outcome of fecal microbiota transplantation for patients with irritable bowel syndrome.

O. Gilja, J. Hatlebakk, M. El-Salhy, 2023, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

The outcome of primary per oral endoscopic myotomy (POEM) for treatment of achalasia: Norwegian single-center experience with long-term follow-up

O. Gilja, J. Assmus, E. Tjora, 2022, Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society.

Endoscopic ultrasound: a new look at achalasia?

S. Ødegaard, J. Hatlebakk, 1998, European journal of gastroenterology & hepatology.

Mucosal blood flow measurements using laser Doppler perfusion monitoring.

Hans Gregersen, H. Gregersen, Dag Arne Lihaug Hoff, 2009, World journal of gastroenterology.

The effect of Helicobacter pylori eradication on gastro‐oesophageal reflux

J. Hatlebakk, A. Berstad, Hatlebakk, 1999, Alimentary pharmacology & therapeutics.

Health and Quality of Life Outcomes

J. Gisbert, D. Bouhassira, L. Agréus, 2008 .

Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational study

J. Gisbert, L. Agréus, J. Nuevo, 2009, Health and quality of life outcomes.

Navigated retrograde endoscopic myotomy (REM) for the treatment of therapy‐resistant achalasia

A. Viste, T. Langø, R. Mårvik, 2017, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Impact of gastroesophageal reflux disease on patients' daily lives: a European observational study in the primary care setting

J. Gisbert, L. Agréus, J. Zapardiel, 2009, Health and Quality of Life Outcomes.

Effect of a cod protein hydrolysate on postprandial glucose metabolism in healthy subjects: a double-blind cross-over trial

T. Hausken, E. Lied, I. Brønstad, 2018, Journal of nutritional science.

Randomised clinical trial: a comparison between a GerdQ‐based algorithm and an endoscopy‐based approach for the diagnosis and initial treatment of GERD

B. Moum, J. Hatlebakk, C. Jonasson, 2012, Alimentary pharmacology & therapeutics.

284 Laparoscopic Antireflux Surgery vs Long-Term Esomeprazole Treatment for Chronic GERD. Final Results After 5 Yrs of Follow up in the Lotus Study

C. Ell, J. Galmiche, L. Lundell, 2010 .

Editorial: the diminishing returns of normalisation of the oesophageal mucosa―Authors' reply

C. Ell, J. Galmiche, L. Lundell, 2017, Alimentary pharmacology & therapeutics.

Long-term effect on symptoms and quality of life of maintenance therapy with esomeprazole 20 mg daily: a post hoc analysis of the LOTUS trial

C. Ell, J. Galmiche, L. Lundell, 2015, Current medical research and opinion.

Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study

I. F. Tvete, J. Hatlebakk, C. Jonasson, 2013, Scandinavian journal of gastroenterology.

Correct use of proton pump inhibitors for gastro-oesophageal reflux disease.

T. Hausken, J. Hatlebakk, B. Emken, 2013, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

Clinical and Experimental Gastroenterology Chronic Fatigue in Patients with Unexplained Self-reported Food Hypersensitivity and Irritable Bowel Syndrome: Validation of a Norwegian Translation of the Fatigue Impact Scale

A. Berstad, J. Hatlebakk, J. Valeur, 2022 .

Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction–Recommendations of the Nordic Working Group

A. Drewes, M. Simrén, L. Agréus, 2016, Scandinavian journal of pain.